Interior minister graces graduation ceremony at Naif Arab University for Security Sciences    Prophet's Mosque imam underscores Islam's core values at peace conference in India    Saudi, Indian foreign ministers co-chair Cooperation Committee meeting in New Delhi    198 new sites documented in the National Antiquities Register    Cityscape Global 2024: Saudi real estate sector booms with SR180 billion in new projects    PIF to sell 2% stake in stc via accelerated book-building    SAMA issues rules for opening electronic wallets    TGA suspends 2 passenger transport applications and an application for food delivery    South Korean actor Song Jae Lim found dead at 39    Trump names Fox News host Pete Hegseth as defense secretary pick    There is nowhere safe in Gaza, UNRWA director says    Archbishop of Canterbury resigns over Church abuse scandal    US says it will not limit arms transfers to Israel    Don't sit on the toilet for more than 10 minutes, doctors warn    Saudi Champion Saeed Al-Mouri scores notable feat in Radical World Championship in Abu Dhabi with support from Bin-Shihon Group    'Marvels of Saudi Orchestra' to dazzle audience in Tokyo on Nov. 22    Rita Ora is tearful in tribute to Liam Payne at MTV Awards    France to deploy 4,000 police officers for UEFA Nations League match against Israel    Al Nassr edges past Al Riyadh with Mane's goal to move up to third    Al Ahli continues strong form with 2-0 win over Al Raed in Saudi Pro League    India puts blockbuster Pakistani film on hold    The Vikings and the Islamic world    Filipino pilgrim's incredible evolution from an enemy of Islam to its staunch advocate    Muted Eid celebrations for millions of Nigerian Muslims    Exotic Taif Roses Simulation Performed at Taif Rose Festival    Asian shares mixed Tuesday    Weather Forecast for Tuesday    Saudi Tourism Authority Participates in Arabian Travel Market Exhibition in Dubai    Minister of Industry Announces 50 Investment Opportunities Worth over SAR 96 Billion in Machinery, Equipment Sector    HRH Crown Prince Offers Condolences to Crown Prince of Kuwait on Death of Sheikh Fawaz Salman Abdullah Al-Ali Al-Malek Al-Sabah    HRH Crown Prince Congratulates Santiago Peña on Winning Presidential Election in Paraguay    SDAIA Launches 1st Phase of 'Elevate Program' to Train 1,000 Women on Data, AI    41 Saudi Citizens and 171 Others from Brotherly and Friendly Countries Arrive in Saudi Arabia from Sudan    Saudi Arabia Hosts 1st Meeting of Arab Authorities Controlling Medicines    General Directorate of Narcotics Control Foils Attempt to Smuggle over 5 Million Amphetamine Pills    NAVI Javelins Crowned as Champions of Women's Counter-Strike: Global Offensive (CS:GO) Competitions    Saudi Karate Team Wins Four Medals in World Youth League Championship    Third Edition of FIFA Forward Program Kicks off in Riyadh    Evacuated from Sudan, 187 Nationals from Several Countries Arrive in Jeddah    SPA Documents Thajjud Prayer at Prophet's Mosque in Madinah    SFDA Recommends to Test Blood Sugar at Home Two or Three Hours after Meals    SFDA Offers Various Recommendations for Safe Food Frying    SFDA Provides Five Tips for Using Home Blood Pressure Monitor    SFDA: Instant Soup Contains Large Amounts of Salt    Mawani: New shipping service to connect Jubail Commercial Port to 11 global ports    Custodian of the Two Holy Mosques Delivers Speech to Pilgrims, Citizens, Residents and Muslims around the World    Sheikh Al-Issa in Arafah's Sermon: Allaah Blessed You by Making It Easy for You to Carry out This Obligation. Thus, Ensure Following the Guidance of Your Prophet    Custodian of the Two Holy Mosques addresses citizens and all Muslims on the occasion of the Holy month of Ramadan    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Want to lose weight? Pills alone won't help
By Debra Sherman
Published in The Saudi Gazette on 24 - 01 - 2009

loss drug approved for sale over-the-counter in the United States, are finding what they likely suspected all along: pills are no magic substitute for diet and exercise.
Yet as Americans engage in the New Year's tradition of resolving to shed pounds, the market for diet aids is expected to remain firm, even as the economy is mired in recession.
Americans spend $30 billion a year on weight-loss products and services, and two-thirds of the population is overweight or obese.
GlaxoSmithKline's Alli, a lower-strength version of Roche's prescription-only Xenical, created' a stir when it was approved 18 months ago.
Since then, it has become known for its unpleasant side effects, including incontinence, diarrhea and flatulence with “oily spotting.”
“It works to inhibit absorption of fat from our diet. Therefore the fat comes out in the stool, causing diarrhea, which patients don't like much,” said Shirley TerMolen, a Chicago internist.
Because the side effects result from eating too much fat, TerMolen noted that some of her colleagues use the drug to help patients modify their behavior.
TerMolen said she has prescribed the drug but has not seen a lot of success. “For most people, they're just looking for a shortcut instead of just eating better and exercising,” she said.
Donald Hensrud, a weight management specialist at Mayo Clinic, called the gastrointestinal side effects overstated. But, he added, the intended effect “is also overrated.”
“People who took the drug lost only 4 more pounds (1.8 kg) than the placebo group after a year. People have to ask themselves whether the expense of this medicine is worth a few extra pounds,” Hensrud said.
A 30-day supply of Alli costs $60.
People who took Xenical, the prescription strength version, lost an average of 5 to 7 additional pounds (2.2 to 3.2 kg) after a year compared with those who took a placebo. Still, experts say weight loss of 5 percent to 10 percent is a worthy goal and a point where health improves.
Meanwhile, Alastair Wood, who chaired the Food and Drug Administration advisory panel that reviewed Alli in 2006, said he's not convinced the drug is being used by the people who would benefit most. In some cases, it is abused by people with eating disorders, he said.
“It's a juxtaposition of an epidemic of obesity with the hope and expectation that we can treat it pharmaceutically,” said Wood.
Glaxo stresses Alli is not a “miracle pill” and that patients should adhere to a low-calorie, low-fat diet and engage in regular exercise.
Roger Scarlett-Smith, the company's president of consumer healthcare in North America, said 5 million people have tried it so far and he expects that number to ramp up in the first quarter, a strong season for weight-loss products.
It was approved for over-the-counter sale in Europe this week.
Disappointment
The history of weight-loss drugs has been fraught with disappointments.
One of the most high-profile was Fen-phen, a cocktail of fenfluramine and phentermine, which was taken off the market in 1997 after it was linked to valvular disease.
Also in 1997, the FDA approved Abbott Laboratories' Meridia, or sibutramine, which blocks chemicals in the brain involved in regulating appetite. The drug was linked to hypertension.
Sanofi-Aventis sells Acomplia, or rimonabant, in Europe, but not in the United States. FDA rejected it in 2007 on concerns it causes neurological and psychiatric problems.
There are few promising treatments in the pipeline at a time when obesity is emerging as one of the biggest health crises facing the developed world.
Earlier this month, Orexigen Therapeutics unveiled results from a late-stage trial of its experimental drug Contrave, which fell short of the bar set by U.S. regulators.
Another candidate is Arena Pharmaceuticals' lorcaserin. A mid-stage trail showed the drug fared well in helping patients lose weight. Late-stage results are due in March. Pfizer, one of several drug makers to drop development of a weight-loss drug from a once promising class that was found to cause psychiatric side effects, said it continues to pursue obesity treatments.
“Some of the late-stage products ... not just Pfizer's pipeline but several other companies' pipelines, have not been successful,” Pfizer Chief Executive Jeff Kindler told the Reuters Health Summit in November.
“It involves so many different aspects. It's not just the biological and potentially hereditary issues, but there are behavioral and cultural issues associated with that. From a medical point of view, it is a tough nut to crack.”
Merck & Co said it too was putting major resources into combating obesity after halting development of a drug that works on the same part of the brain that makes people hungry after smoking marijuana.
New treatments are years away. In the meantime, consumers will likely continue to buy what's out there.
“I think (Alli) will probably be around for a long time to come. It's a smart drug more from a marketing standpoint than from a clinical efficacy standpoint,” Mayo's Hensrud said. “This is a multibillion-dollar industry.”


Clic here to read the story from its source.